Side effects of Bacillus Calmette-Guérin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full d (Q38447327)
Jump to navigation
Jump to search
scientific article published on 24 July 2013
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Side effects of Bacillus Calmette-Guérin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full d |
scientific article published on 24 July 2013 |
Statements
Side effects of Bacillus Calmette-Guérin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG (English)
Richard Sylvester
Willem Oosterlinck
Maurizio Brausi
Aldo Bono
Cees van de Beek
George van Andel
Levent Turkeri
Sandrine Marreaud